Publications by authors named "P Jilma-Stohlawetz"
Background: In newborns, elevated nucleated red blood cell (NRBC) levels can be associated with enhanced erythropoietic stress and might be predictive for adverse outcome. Also, the presence of NRBC in peripheral blood might lead to erroneous enumeration results of white blood cells in automated hematology analyzers. We aimed to assess the comparability of the Sysmex XN 1000 to manual slide reviews and correlation of NRBC with inflammation markers.
View Article and Find Full Text PDFArticle Synopsis
- Factor VIII (FVIII) is a crucial protein for blood clotting, and its half-life in circulation is influenced by von Willebrand Factor (VWF); recent research introduced rondaptivon pegol, a VWF-binding aptamer, which boosts VWF and FVIII levels in healthy individuals.
- A clinical trial involving 19 adult patients with varying degrees of hemophilia A assessed the safety, pharmacokinetics, and effects of rondaptivon pegol, with results showing a well-tolerated treatment that effectively increased VWF and FVIII activity.
- The study found that treatment with rondaptivon pegol extended the half-life of FVIII products significantly (from about 10.4 hours
Type 2B von Willebrand disease (VWD) is characterized by an increased binding affinity of von Willebrand factor (VWF) to platelet glycoprotein Ib. This can lead to clearance of high-molecular-weight (HMW) multimers and thrombocytopenia with a resulting moderate-severe bleeding phenotype. Rondoraptivon pegol (BT200) is a pegylated aptamer binding to the A1 domain of VWF with a novel mechanism of action: it enhances VWF/factor VIII (FVIII) levels by decreasing their clearance.
View Article and Find Full Text PDFVon Willebrand factor (VWF) and factor VIII (FVIII) circulate in a noncovalent complex in blood and promote primary hemostasis and clotting, respectively. A new VWF A1-domain binding aptamer, BT200, demonstrated good subcutaneous bioavailability and a long half-life in non-human primates. This first-in-human, randomized, placebo-controlled, doubleblind trial tested the hypothesis that BT200 is well tolerated and has favorable pharmacokinetic and pharmacodynamic effects in 112 volunteers.
View Article and Find Full Text PDFIntroduction: The aim of this study was to evaluate the Hemoclot Quanti. V-L assay in various clinical conditions.
Methods: We compared the Hemoclot Quanti.